NAD+
Nicotinamide Adenine Dinucleotide / NAD
NAD+ (nicotinamide adenine dinucleotide) is a critical coenzyme present in every living cell, functioning as an essential electron carrier in mitochondrial energy production and as a substrate for sirtuins, PARPs, and CD38 enzymes involved in DNA repair and cellular signaling. Declining NAD+ levels are strongly associated with aging and metabolic dysfunction, making NAD+ repletion a major focus of longevity research. It is administered via IV infusion, subcutaneous injection, or oral precursors (NMN, NR) in anti-aging and neurological research protocols.
作用機序
Essential coenzyme present in all living cells. Central to cellular energy metabolism (glycolysis, TCA cycle, oxidative phosphorylation), DNA repair (PARP enzymes), epigenetic regulation (sirtuins), and calcium signaling. Levels decline ~50% between ages 40-60.
研究プロトコル
研究目的のみで使用。医療アドバイスではありません。
Research protocols use 250-750mg via IV infusion over 2-4 hours. Subcutaneous protocols use 50-100mg daily. Intranasal formulations under investigation. IV sessions typically weekly for 4-8 weeks, then monthly maintenance.
研究ノート
Clinical Research Status
NAD+ IV therapy is actively studied in clinical trials for conditions including chronic fatigue, neurodegenerative diseases, substance use disorders, and age-related metabolic decline. The precursors NMN and NR have multiple ongoing Phase I/II trials examining bioavailability, safety, and effects on aging biomarkers. While IV NAD+ clinics have proliferated globally, FDA-approved therapeutic indications remain limited to experimental and integrative medicine settings.
Key Published Findings
Research has demonstrated that NAD+ levels decline by approximately 50% between ages 40 and 60, correlating with mitochondrial dysfunction and increased disease susceptibility. Studies in animal models show that NAD+ repletion restores mitochondrial function, improves insulin sensitivity, and extends healthspan markers. Human trials with NR supplementation have confirmed dose-dependent increases in blood NAD+ levels with good tolerability, though functional clinical endpoints are still being validated.
Safety Profile
IV NAD+ infusions are generally well-tolerated but commonly produce transient side effects including chest tightness, nausea, abdominal cramping, and flushing during infusion, which are managed by slowing the drip rate. Oral precursors NMN and NR show excellent safety profiles in clinical doses of 250-1000mg daily with minimal adverse events reported. Theoretical concerns exist about long-term high-dose NAD+ supplementation potentially fueling growth of existing cancers, though clinical evidence for this remains inconclusive.
Drug Interactions & Contraindications
NAD+ may interact with blood pressure medications due to its vasodilatory effects during IV administration. Caution is advised with concurrent use of chemotherapeutic agents, as NAD+-dependent PARP inhibitors may have altered efficacy. Patients with active malignancies should consult their oncologist before beginning NAD+ therapy given the theoretical role of NAD+ in supporting cellular proliferation.
Comparison to Related Compounds
NMN (nicotinamide mononucleotide) is a direct NAD+ precursor requiring one enzymatic step for conversion, offering potentially faster NAD+ elevation than NR. NR (nicotinamide riboside) has more published human clinical trial data and established commercial availability as a supplement (TruNiagen, Elysium). Direct IV NAD+ bypasses the need for enzymatic conversion entirely but requires clinical administration and produces more acute side effects than oral precursors.
Community Observations
Users of IV NAD+ commonly report initial sessions being uncomfortable due to nausea and chest tightness, with subsequent sessions becoming more tolerable as the body adapts. Many practitioners administer loading protocols of 500-1000mg IV daily for 3-5 days followed by monthly maintenance infusions. The biohacking community frequently combines NAD+ protocols with resveratrol and fasting to maximize sirtuin activation and perceived anti-aging benefits.
半減期
~45 minutes (IV)
再構成
Sterile saline for IV; bacteriostatic water for SubQ
保存
乾燥粉末
Refrigerate 2-8C. Protect from light.
再溶解
Use within 24 hours of preparation (IV). SubQ: within 7 days.
米国法的状況
また知られる名前
よくある質問
NAD+とは何ですか?
NAD+ (nicotinamide adenine dinucleotide) is a critical coenzyme present in every living cell, functioning as an essential electron carrier in mitochondrial energy production and as a substrate for sirtuins, PARPs, and CD38 enzymes involved in DNA repair and cellular signaling. Declining NAD+ levels are strongly associated with aging and metabolic dysfunction, making NAD+ repletion a major focus of longevity research. It is administered via IV infusion, subcutaneous injection, or oral precursors (NMN, NR) in anti-aging and neurological research protocols.
NAD+はどのように作用しますか?
Essential coenzyme present in all living cells. Central to cellular energy metabolism (glycolysis, TCA cycle, oxidative phosphorylation), DNA repair (PARP enzymes), epigenetic regulation (sirtuins), and calcium signaling. Levels decline ~50% between ages 40-60.
NAD+の米国での規制状況は?
Supplement (not FDA-regulated as drug)
NAD+の半減期は?
~45 minutes (IV)
NAD+の別名は?
Nicotinamide Adenine Dinucleotide, NAD
ペプチドコンタクトは、研究目的のみのための要約情報を提供しています。私たちはベンダーの文書をホスト、配布、または推奨していません。すべての分析証明書、GMP認定証明書、およびベンダーコミュニケーションは、購入者によって直接要求され、確認される必要があります。このプラットフォーム上の何らかの情報は法的、医学的、または専門的なアドバイスを構成していません。ユーザーは、適切な法律、州法、および連邦法に準拠するためにベンダー資格を検証し、購入前に遵守することに全責任を持つ必要があります。このプラットフォームを使用することで、完全な個人的責任を承認することになります。
完全な免責事項を読む